Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials
Date:5/9/2013

e commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product using the BEMA technology, BEMA Buprenorphine, is currently in Phase 3 trials for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions.  BDSI's third pain product in development is Clonidine Topical Gel for the treatment of painful diabetic neuropathy, which is licensed from Arcion Therapeutics.

Additionally, BDSI is developing BUNAVAIL, a high dose formulation of buprenorphine in combination with naloxone for the treatment of opioid dependence.  Both BEMA Buprenorphine and BUNAVAIL are in Phase 3 clinical development, and Clonodine Topical Gel is in Phase 2 clinical development. 

BDSI's headquarters is located in Raleigh, North Carolina.  For more information visit www.bdsi.com.

Cautionary Note on Forward-Looking Statements

This press release, the presentation referred to herein, and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the curre
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Second Quarter 2012 Financials
2. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. R. Graham Cooks Wins Dreyfus Prize in the Chemical Sciences; Purdue Chemist Honored for Advances in Chemical Instrumentation
5. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
6. Best Practices for Conducting Extractable and Leachable Studies, new life sciences webinar hosted by Xtalks
7. Tunnell Consulting Names John S. Ross as Principal, Life Sciences
8. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
9. Partnership between EBSCO Publishing and BioOne Online Journals Adds Scholarly Biological, Ecological and Environment Sciences Articles to EBSCO Discovery Serviceā„¢
10. MedeAnalytics Ken Perez Predicts Rapid Growth of Healthcare Data Analytics Market at Conference on Data Analytics in Life Sciences, Healthcare and Biotech Companies
11. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... history lessons often have it that American Indians largely ... chicken pox, influenza and tuberculosis brought to the New ... vary, about 20 million people lived in the Americas ... them were killed by European diseases., But new research ... University and Johannes Krause of the University of Tubingen ...
(Date:8/20/2014)... 2014 Neurotrope, Inc. (OTCQB: NTRP) today ... to provide an update on Company activities. Access ... numbers:(888) 505-4369 (U.S. and Canada) or (719) 325-2315 ... , under "Investor Relations"The teleconference replay will be ... 2, 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds that the vascular access ... , India and China ... roughly equal to the size of the United States ... will experience much faster growth as a result of strong economic ... Other key findings from Decision Resources Group,s coverage of the BRIC ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Neurotrope To Host Conference Call 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2
... company adds new apoAI measurement and apoB/apoAI ratio to ... March 17 /PRNewswire/ -- Atherotech, ... Cholesterol Test in booth #1263 at ACC.09, the American ... The annual meeting takes place March 29-31, 2009, at ...
... Mass., March 17 The pro bono healthcare ... ), has announced that its newly instituted Safe ... Lutheran Health System of La Crosse, Wisconsin. The ... outstanding accomplishments in safe patient handling, safe lifting, ...
... March 17 Cardiorobotics, Inc., a ... use in a wide range of applications, including: ... appointment of Dr. Samuel Straface in the position ... that Dr. Straface has joined Cardiorobotics in this ...
Cached Biology Technology:Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando 2Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando 3Gundersen Lutheran Health System is Recognized for Safe Lifting Leadership 2Gundersen Lutheran Health System is Recognized for Safe Lifting Leadership 3Cardiorobotics Announces New CEO, PLSG Executive-in-Residence to Lead Company 2Cardiorobotics Announces New CEO, PLSG Executive-in-Residence to Lead Company 3
(Date:8/20/2014)... burning spiciness that is irresistible to some, but intolerable ... using their findings to develop a new drug candidate ... by inflammation or other problems. They reported their progress ... trials, in ACS, Journal of Medicinal Chemistry . ... scientists had pegged a compound called capsaicin as the ...
(Date:8/20/2014)... by researchers at the University of Missouri School of ... life-threatening heart condition caused by muscular dystrophy. , ... Ph.D., the leading author of the study and assistant ... of Molecular Microbiology and Immunology. "This is just a ... a treatment for people with this devastating heart condition, ...
(Date:8/20/2014)... and POINT ROBERTS, Washington , August ... a Key Role in Addressing Security Concerns in the Payment ... global news source covering leading sectors including biometrics, issues commentary ... Jason Peaslee , Managing Partner at Thrive ... Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: NXTD) ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7
... Tampa, Fla. (April 11, 2011) ... be the most efficacious of three kinds of clinically ... in the current issue of Cell Transplantation ... to researchers in Seoul, South Korea, transplantation of PDLSCs ...
... Human umbilical cord blood-derived mensenchymal stem cells (uMSCs) have ... (LN) when transplanted into mouse models of systemic lupus ... immune system aberrations" characterized by diverse clinical conditions, including ... patients with SLE., The beneficial results were reported in ...
... Scientists have moved a step closer to being able to ... technique to map both the connections and functions of nerve ... A new area of research is emerging in the neuroscience ... our genetic make-up, connectomics aims to map the brain,s connections ...
Cached Biology News:Periodontal stem cell transplantation shows promise 2Umbilical cord blood-derived stem cells studied for lupus therapy 2Mapping the brain: New technique poised to untangle the complexity of the brain 2Mapping the brain: New technique poised to untangle the complexity of the brain 3
...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... types of yeast two-hybrid studies, including complex interaction studies ... Choice of two bait vectors for maximum flexibility and ... Triple reporter strain NMY51 ensures an ... Complete set of controls: pLexA-p53, pLexA-lamin C and ...
Biology Products: